Home / Companies / Allogene Therapeutics, Inc. / 5 Jun 2024
Allogene Therapeutics, Inc.: meeting of 5 Jun 2024
Votes reported on Form N-PX, item by item
256 Form N-PX filers reported votes at the Allogene Therapeutics, Inc. meeting of 5 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
4 nominees; 50.1% of reported votes for; 63 filers withheld from or voted against at least one nominee.
821 vote records from 110 filers. 42 of the 108 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
391 vote records from 255 filers. 133 of the 242 filers that marked the item either way voted against management. 13 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
205 vote records from 109 filers. 0 of the 107 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | Abstain or withhold * | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Invesco | For | Against * | For |
| Equitable | For | Against * | For |
| Charles Schwab | Split or no vote | Against * | For |
| Nuveen and TIAA | Split or no vote | Against * | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | Abstain or withhold * | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | Abstain or withhold * | Against * | For |
| PGIM and Prudential | For | Against * | For |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | For | For | For |
| T. Rowe Price | Split or no vote | Against * | For |
| Lincoln Financial | Abstain or withhold * | For | For |
| Voya | Split or no vote | Against * | For |
| Nationwide | Abstain or withhold * | Against * | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Brighthouse Funds | For | For | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | Abstain or withhold * | Against * | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| Transamerica | Split or no vote | Against * | For |
| Federated Hermes | For | For | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Abstain or withhold * | Against * | For |
| Harbor Funds | For | For | For |
| Macquarie and Delaware Funds | Abstain or withhold * | Against * | For |
| Janus Henderson | No report | Against * | No report |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Allogene Therapeutics, Inc. meeting?
256 Form N-PX filers reported votes at the meeting of 5 Jun 2024. On say-on-pay, 133 of 242 voted against management (55.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Allogene Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Allogene Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Allogene Therapeutics, Inc. with a meeting date within three days of 5 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.